Who We Are
Lucence Diagnostics is a genomic medicine company focused on personalizing cancer care. We invent novel liquid biopsy tests for cancer detection and treatment. We target common cancers in Asia, such as cancers of the lung, breast, colon, liver and nasopharyngeal. We deliver our clinical services worldwide through an ISO 15189:2012 accredited laboratory.
A world without avoidable cancer deaths.
To achieve early cancer detection, better treatment and less suffering through deep genome intelligence.
We see the fight against cancer as a mission. If we can deliver early detection for all cancers to achieve cure, that is something worth our time, our energy, everything.
The story of Lucence Diagnostics began in 1999, when our founder Dr Min-Han Tan (Han) was a medical resident at the university cancer center in Singapore. There he witnessed great suffering, but also saw the ability of modern medicine to alleviate unnecessary pain and distress. This formative experience motivated him to focus his life and career on understanding how to fight and defeat cancer through a deep understanding of the human genome. Han believes that oncology exists where bedside medicine, high technology, deep research and profound spirituality intersect.
Han first completed his medical oncology specialist training. He then went on to pursue his PhD in cancer genetics at the Karolinska Institute, Sweden and National University of Singapore. To seek deeper understanding on genomic medicine, Han joined the Cleveland Clinic in the United States as a research scholar, where he was awarded both the Lee Foundation and Ambrose Monell Cancer Genomic Medicine Fellowships. At the Cleveland Clinic, he and Professor Charis Eng published landmark data models on cancer risk in hereditary breast and thyroid cancers. This work continues to guide the international cancer community in patient care today.
In 2011, Han joined the Agency for Science, Technology and Research (A*STAR) to lead the Laboratory of Systems Medicine and focus on building better genomic technology for cancer patients. Over the next 5 years, Han and his team made key discoveries on the nature of circulating tumor DNA and circulating tumor cells by applying innovative laboratory and machine-learning technologies. His discovery of the circulating tumor-endothelial cluster transformed the liquid biopsy field and overturned decades of scientific dogma. This research led to improved non-invasive screening and profiling of cancer using blood testing.
Han founded Lucence in 2016 to deliver his genomic technology from the laboratory to the world where it was most needed. Lucence’s vision is a world without avoidable cancer deaths through early cancer detection and better treatment selection. The company’s AmpliMARK™ sequencing technology is used in its flagship liquid biopsy test LiquidHALLMARK® to detect cancer-causing mutations and viruses. Its AI platform SunTzu.AI™ centralizes genomic intelligence and maps cancer-fighting strategies for each patient.
In 2017, Lucence raised US$9.2 million in seed funding, one of the largest seed investments raised by a biomedical start-up in Asia Pacific. Today, Lucence’s liquid biopsy tests are available across Asia to help doctors reduce the pain and sufferings of cancer patients.
Achieving a world without avoidable cancer deaths through genomic intelligence is at the core of everything Lucence does.
Raised US$9.2 million seed funding
ISO 15189:2012 accreditation
Company expands to Hong Kong
Company expands to San Francisco
Company expands to Suzhou
We are a venture-backed company with the mission to fight cancer through earlier diagnosis and treatment. We are supported by a group of like-minded investors that understands how great technology is nurtured and developed, the positive impact it can have on lives, and the real difference it can make to humanity.
We partner with healthcare providers and medical laboratories to deliver our cancer diagnostic services to physicians. We also collaborate with hospitals, research institutes and universities to conduct studies that advance the field of genomic medicine.
CEO and Medical Director
Min-Han (Han) is the Founding CEO and Medical Director of Lucence Diagnostics. He is also a visiting consultant at the Division of Medical Oncology, National Cancer Centre Singapore (NCCS), and a visiting scholar at the Faculty of Engineering, Waseda University, Japan. A trained medical oncologist and clinical cancer geneticist, Han obtained his MBBS and PhD from National University of Singapore. He completed his cancer specialist training at NCCS. In 2011, he joined the Agency for Science, Technology and Research (A*STAR) in Singapore to lead the Laboratory of Systems Medicine. Han started Lucence in 2016 to commercialize the liquid biopsy technology his lab developed at A*STAR. Han has published over 100 original research publications and filed 13 patents. He was elected Fellow of the Royal College of Physicians Edinburgh in 2015 and received the A*STAR Outstanding Scientist-Entrepreneur Award in 2018.
Chief Technology Officer
Yukti is the Chief Technology Officer and co-founder of Lucence Diagnostics. A molecular biologist by training, she holds a PhD in Biological Sciences and a BSc (first class honors) in Life Sciences from National University of Singapore. At Lucence, Yukti is responsible for creating new molecular diagnostic technology for cancer detection and treatment. She leads a team of scientists and data professionals to harness the genomic information of patients for better clinical decision-making. Prior to Lucence, she was a research scientist at the Agency for Science, Technology and Research (A*STAR). Yukti has made breakthrough discoveries of new treatment targets for brain and kidney cancers. Notably, she developed the first patient-specific, stem cell-based method for modeling drug-induced liver toxicity. Yukti has been recognized for her scientific contributions by the American Society of Clinical Oncology and was named a “Promising Young Investigator” by the Kidney Cancer Association in 2016.
Chief Commercial Officer
Pan is the Chief Commercial Officer and co-founder of Lucence Diagnostics. She leads the commercialization of our proprietary cancer diagnostic tests from bench to bedside. Pan is an advocate for precision medicine and genetic testing. She has been working in the field of molecular diagnostics focusing on oncology and infectious diseases for over 10 years. Prior to Lucence, Pan managed sales and marketing for multinational diagnostics companies covering the United States, Europe, China and Southeast Asia. She has also successfully developed and commercialized several cutting-edge diagnostic tools and methods. Pan holds a PhD in Microbiology from National University of Singapore.
Chief Financial Officer
With over 10 years of experience in accounting, assurance, and taxation, Kevin oversees the financial operations of the company. His assurance background with KPMG has given him a keen understanding of company growth, compliance needs, and project management. In his previous role as the Financial Controller of a listed healthcare company, he developed his skills in operations and workflow management. He is a chartered accountant and holds a Bachelor’s degree in Accountancy from Nanyang Technological University. Kevin is also a seven-time national chess champion, a globally recognized chess writer, and Singapore’s next Chess Grandmaster.
Wai Min Phyo
Wai Min drives assay development and quality assurance at Lucence. Trained in medicine and engineering, he has a track record of successful technology licensing to industry. Prior to Lucence, Wai Min worked at Dr. Min-Han Tan’s lab at the Agency for Science, Technology and Research (A*STAR), where he developed novel PCR-based diagnostics that have been commercialized for real-world clinical usage. He was also instrumental in setting up a tissue bank for research and development in colorectal cancer, a collaboration between A*STAR and Fortis Colorectal Hospital. He holds an MBBS from University of Medicine (I), Yangon and a Master’s degree in Engineering from National University of Singapore.
Jamen leads business development at Lucence to identify and win new customers across the globe. Prior to this position, he successfully expanded our operations to Hong Kong and led sales and marketing for Singapore. Jamen has strong business acumen and customer relationship skills. He previously founded four companies across various industries such as medical logistics, travel, education and events management. Jamen holds a BEng from National University of Singapore.
Jack is responsible for organizing the diverse data streams that empower cancer patients and healthcare providers to make the best treatment decisions possible. Based in San Francisco, he also helps Lucence maximize research and commercial opportunities in the United States. An entrepreneur at heart, Jack previously co-founded CliniCast – a startup that helped providers in the US and Singapore organize complex cancer information for research and patient treatment. After Elekta acquired CliniCast in 2015, he helped grow Elekta’s operational analytics portfolio to a global customer base. Jack holds a PhD in Physics from Yale University.
Hao currently oversees the growth and architecture of our AI-driven data analytics platform SunTzu.AI™, which spans genetics and image-based approaches to precision medicine. He has an accomplished track record of creating highly innovative software platforms for analyzing biological and cellular diversity at the Agency for Science, Technology and Research (A*STAR). Regularly ranked among the top downloads on Bioconductor, the primary open-source biological software repository in the world, his algorithms provide insights on high-dimensional and high-throughput single-cell complex data analysis. Hao’s work has been published in top peer-reviewed journals, and he has filed patents on technology for automated and reproducible analysis of complex data. He received his BSc in Biotechnology from Harbin Institute of Technology (China) and MSc in Bioinformatics from Nanyang Technological University (Singapore).
Jess oversees operational matters and manages key projects at Lucence. She is adept at navigating business growth and operations with her profound understanding of team dynamics. Prior to joining Lucence, she worked in Dr. Min-Han Tan’s lab at the Agency for Science, Technology and Research (A*STAR). There, she led and published several key research studies in cancer diagnostics and liquid biopsies. She co-invented a liquid biopsy test that detects early-stage nasopharyngeal cancer which has been commercialised at Lucence. Jess has also been key in the successful filing of new patents at Lucence with her experience in intellectual property management. She graduated with a BSc (Hons) in Biological Sciences from Nanyang Technological University.
Regional Director and Product Management Head
Hilary is the regional director for Hong Kong, Macau and Taiwan. She is also responsible for product management at Lucence. With her deep expertise in both the commercial and technical aspects of biotechnology, she focuses on delivering our flagship liquid biopsy test to physicians and patients. Hilary comes with extensive international experience growing medical diagnostics across Asia, Europe, Africa, Middle East and Latin America. She holds a BSc in Biological Sciences from The University of Hong Kong and a MSc in Marketing from City University of Hong Kong.
Market Lead (China)
Aster leads market development for Lucence in Mainland China. She has more than 5 years of sales and marketing experience in diagnostics and cancer screening across South East Asia and Hong Kong. Aster holds a MSc from Hong Kong Baptist University.
People & Organisational Development
People & Organisational Development
Yvonne focuses on people development and organisational effectiveness at Lucence. She holds a Bachelor of Arts from Kyoto University and is proficient in Japanese. Yvonne enjoys learning foreign languages and being a part of multicultural environments.
Benson oversees the legal aspects of Lucence’s multi-jurisdictional and rapidly growing businesses. He is called to the Singapore Bar and admitted as a solicitor in England and Wales. Bensons holds an LLB from the National University of Singapore.
Assistant Corporate Counsel
Genevieve supports the management of Lucence’s legal matters. She was previously a legal counsel at SingHealth, focused on agreements and matters in relation to the research portfolio of SingHealth. Genevieve is called to the Singapore Bar and holds an LLB from the National University of Singapore.
Hilda is responsible for expanding our business operations to new markets in Asia. Hilda has extensive frontline experience in the healthcare and biomedical sectors, which enables her to build strong working relationships with new and existing customers. She holds a BSc in Biomedical Sciences from the University of Bradford.
Senior Sales Manager,
Jack comes with extensive oncology sales experience in the pharmaceutical industry, covering the hospitals and clinics in Hong Kong and Macau. Prior to Lucence, she was a customer liaison manager at Innovative Diagnostics. At Lucence, she is responsible for promoting the adoption of our cancer diagnostic tests among the medical professionals in Hong Kong. Jack has a certificate in Nursing from The Grantham Hospital, Hong Kong.
King is responsible for promoting the adoption of our cancer diagnostic tests by healthcare professionals in Hong Kong. He comes with over 10 years of sales experience in multinational pharmaceutical and life science companies such as MSD, Janssen, Otsuka, Cirina and Grail. King holds a BSc in Biomedical Engineering from the Hong Kong Polytechnic University and a MSc in Psychology from Hong Kong Shue Yan University. He is also a certified fitness trainer and a marathon runner.
Sales and Marketing Executive
In her pursuit of a Bachelor’s degree in Biomedical Engineering from the National University of Singapore, Yuzhen developed microfluidic devices for the separation of circulating tumor cells from peripheral blood. While in university, she also underwent an internship with GE Healthcare as a Clinical Marketing Specialist, which exposed her to the healthcare industry and gained experienced in product marketing. Yuzhen joined Lucence to drive the adoption of our cancer diagnostic tests through marketing and sales. She also builds brand awareness and promotes Lucence’s work through the conception of marketing collaterals, corporate communications activities, and digital media management on multiple platforms. Yuzhen is a competitive volleyball player.
Sales and Marketing Executive,
Caitlyn handles sales and marketing for Lucence’s Hong Kong office. While in university, she did two marketing internships with BLOOM Association and GELEC (HK) Limited, where she developed a strong interest in marketing. Caitlin graduated with a Bachelor of Science degree in Biological Science from the University of Hong Kong.
Pow Jia Qi
Jia Qi is responsible for promoting the adoption of our cancer diagnostics tests among medical professionals in Singapore. While in University, she interned in Quest Laboratories as a Medical Technologist. Jia Qi graduated with a Bachelor of Science (Biological Sciences) from Nanyang Technological University and holds a Diploma in Molecular Biotechnology from Nanyang Polytechnic.
Lay Kheng Tan
Lay Kheng oversees day to day operational matters to ensure the smooth running of Lucence’s Genetics Clinic. With her strong background in nursing and deep experience caring for patients with genetic cancer disorders, she positively impacts the lives of all our patients. Lay Kheng has a diploma in nursing from Nanyang Polytechnic.
Daniel Tan Kian Hin
Daniel joined Lucence to pursue his interest in the application of next-generation sequencing (NGS) for clinical research and is now involved in the development and validation of NGS assays to bring the technology from bench to bedside. In his postgraduate candidature in the University of Malaya, Daniel focused on the study of quorum sensing, a form of bacterial communication in an uncommonly studied bacterium, Cedecea neteri.
Michelle is involved in the development of diagnostic assays and clinical reporting. Prior to Lucence, she worked at the Agency of Science, Technology and Research (A*STAR) where she investigated combinatorial targeted therapy in colorectal cancer, and optimized the use of preclinical cancer models for drug development using next-generation sequencing. Michelle was awarded the A*STAR Graduate Scholarship to pursue her PhD in Cancer Biology from the National University of Singapore. She holds a BSc (Hon) in Biological Sciences from Nanyang Technological University.
Ngeow Kao Chin
Kao Chin works on improving the accuracy and sensitivity of our molecular diagnostic assays for cancer detection. Before joining Lucence, he was a research fellow at the Agency of Science, Technology and Research (A*STAR) where he developed new therapies for cancer and fibrosis treatment. Kao Chin was a recipient of the National Science Scholarship from A*STAR. He holds a Sc.B. in Biomedical Engineering from Brown University and a DPhil in Clinical Medicine from the University of Oxford.
Chae Yin Cher
Chae Yin is involved in the development of sequencing platform for cancer diagnostics. Prior to joining Lucence, Chae Yin did her PhD in Hematology at The University of Hong Kong. Her work involved the application of next-generation sequencing in predicting outcomes of patients with myeloid malignancy and investigation of clonal evolution. She was an awardee of the Hong Kong PhD Fellowship Scheme, established by the Research Grants Council of Hong Kong.
Kim Tien Ng
Kim Tien’s main role includes scaling up robotic process automation to improve operational efficiency, productivity and quality. He has received several international Young Scientist Awards in the US, Germany and Japan for his research on the identification and characterization of novel HIV-1 recombinants and the investigation of HIV-1 transmission networks in Southeast Asia. Prior to Lucence, he was a Research Associate at the Duke-NUS Medical School, where he designed the viral and bacterial peptide libraries for potential real-life application in combating disease outbreaks. He holds a PhD in Medical Virology and Molecular Epidemiology from the University of Malaya, during which he developed and patented an improved assay for rhinovirus (RV) quantification.
Siti Farah Bte Fadhlullah
Senior Research Officer
Farah focuses on service development and assay validation at Lucence. She conducted liquid biopsy research at the Agency for Science, Technology and Research (A*STAR) and brain cancer treatment research at the National Neuroscience Institute (NNI). Farah has won numerous awards in her early scientific career, including the Promising Young Researcher Award from A*STAR and the Best Junior Research Presentation Award from NNI’s Academic Clinical Program. She graduated with a BSc (first class honors) in Biological Sciences from Nanyang Technological University.
Albert Ho Yi Liang
Senior Full Stack Engineer
Yi Liang is responsible for developing an automated workflow management system and data analysis platform at Lucence to enhance the delivery of our cancer diagnostic services. Prior to Lucence, he was a researcher at Nanyang Technological University, where he worked on natural language processing to build next-generation search engines such as ontology search. Yi Liang embraces new technologies like augmented reality, blockchain and Smart Home because he believes that great technology makes life better. He received his BBA from the Harbin Institute of Technology and graduate diploma in Systems Analysis from the National University of Singapore.
Thet Naing Aye
Naing is responsible for developing clinical intelligence software applications and services at Lucence. He is passionate about software development and building applications based on best engineering practices. Naing holds a MSc in Construction Management from Nanyang Technology University and BE in Naval Architecture from Myanmar Maritime University. He also has a graduate diploma in Systems Analysis from the Institute of Systems Science, National University of Singapore.
Chaitanya focuses on solving complex medical problems using data science and analytics. Prior to Lucence, he worked extensively on chronic disease management using clustering algorithms during his Master’s. He also worked as a project analyst at Opera Solutions, where he solved classification problems pertaining to hospital billing data and patient information. He has a deep interest in programming and was selected for Google’s Summer of Code for two consecutive years when he was pursuing his undergraduate degree at Jamia Millia Islamia, New Delhi. Chaitanya holds a Master’s degree in Computer Science from the National University of Singapore. He is also a competitive volleyball and badminton player.
Yong Herng Low
Yong Herng oversees laboratory management at Lucence. He played a key role in achieving Lucence’s early milestones of clinical laboratory licensing from the Singapore’s Ministry of Health and ISO 15189 accreditation. Yong Herng joined Lucence from the Singapore General Hospital, where he was a key operator of the External Quality Assurance Program and Safety Program for its biochemistry laboratory. With his background as an underwater combat medic for Singapore’s elite Naval Diving Unit, Yong Herng is skilled in working with highly focused teams to solve complex operational problems. He graduated with a BSc (first class honors) in Medical Bioscience from Aston University.
Deputy Laboratory Manager
Melvin is responsible for maintaining adherence to laboratory protocol and test quality control management. Prior to joining Lucence, he was a research officer at the Khoo Teck Puat Hospital for 8 years. There, he contributed significantly to numerous cohort study publications on endocrinology, focusing on Type 2 Diabetes and obesity. Being at the forefront of clinical research, Melvin has gained extensive experience in analytical methods for proteomic biomarker studies. He is also well equipped with next-generation sequencing skills. He holds a BSc in Biomedical Sciences from the University of Western Australia.
Michelle Tan Bee Kim
Senior Medical Technologist
At Lucence, Michelle performs molecular diagnostic testing on human biological specimens. Prior to Lucence, she was a medical technologist at the Singapore General Hospital and a contract research organisation where she gained extensive experience in genomic testing, particularly in companion diagnostics. She has a BSc (Hons) in Biological and Biomedical Sciences from Nanyang Technological University.
Ru Jin Tay
Senior Medical Technologist
Ru Jin performs and analyzes the results of our liquid biopsy tests. She also ensures the validity of test results based on established quality assurance and quality control procedures. Prior to joining Lucence, she was a medical technologist at Singapore General Hospital. Ru Jin graduated with a BSc in Life Sciences from National University of Singapore.
Marielle performs analysis of patient samples for the various assays offered at Lucence. Prior to Lucence, she was a Medical Technologist at Covance Asia, where she handled the validation of new instruments and assays. She has also worked at Axil Scientific as a Laboratory Officer for Sequencing where she handled the optimization of PCR conditions to deliver higher quality results in a shorter turnaround time. Marielle holds a Diploma in Molecular Biotechnology from Nanyang Polytechnic and a certificate in Basic Industrial Safety and Health Course for Supervisors.
Mai joined Lucence after obtaining her Bachelor of Engineering (Biomedical) at National University of Singapore. Prior to Lucence, she has helped developed PCR-based diagnostic assays at A*STAR under its youth research program and designed bioresorbable bone implants for Osteopore International Pte Ltd as a Product Development Intern. Mai has an interest in public health and volunteers regularly for Project X, a non-governmental organization that promotes women’s health in Singapore.
At Lucence, Nicole is responsible for performing various diagnostic assays. Prior to Lucence, she worked on the identification of microorganisms using sequencing and MALDI-TOF analysis in a contract testing laboratory. Nicole holds a BSc (Hons) in Biological Science from Nanyang Technological University. She is also a competitive floorball player.
Shaun is responsible for performing diagnostic molecular assays here at Lucence for our flagship LiquidHALLMARK™ test. He comes with deep experience from working on various molecular diagnostic tests for Leukaemia and managing the tissue bank at the Cancer Science Institute of Singapore. Shaun holds a Bachelor’s degree in Molecular Biology and Biotechnology from the University of Western Australia.
Ee Wern Kwong
Junior Medical Technologist
At Lucence, Ee Wern is responsible for performing laboratory diagnostic procedures to achieve accurate and reliable test results. She presented her honors project on “Comparative Proteomic Analysis and Immunoreactivity of Two Indonesian Snake Species” at the 9th Malaysian Symposium of Biomedical Science. While in University, she did an internship at the Diagnostics Laboratory of Sunway Medical Centre, Kuala Lumpur. Ee Wern obtained her Bachelor’s degree in Biomedical Science (Hons) from University of Malaya.
Ong Geok Fong
Junior Medical Technologist
Here at Lucence, Geok Fong is responsible for performing various molecular diagnostic assays. While in university, she interned at the University Malaya Medical Centre, Malaysia, as a medical technologist. She also presented her honors project at the 10th Malaysian Symposium Biomedical Science and was awarded Best Poster Presenter. Geok Fong holds a Bachelor’s degree in Biomedical Science(First-class Honors) from the University of Malaya.
Ang Yong Chai
Junior Medical Technologist
Yong Chai is responsible for performing various molecular diagnostic assays offered at Lucence. Prior to Lucence, he was a research assistant at the University of Malaya, where he studied the pathogenesis of neurotropic enteroviruses infections. While at university, he presented his honors project on “Development of In Situ Hybridization Assay for the Detection of EV-D68 RNA in FFPE Tissue” at the 9th Malaysian Symposium of Biomedical Science and was awarded Champion for Poster Presentation (Infectious disease category). Yong Chai graduated with a BSc (First Class Honors) in Biomedical Science from University of Malaya.
Jennifer assists in accounting and procurement matters at Lucence. She graduated with a BSc in Accounting and Finance (Hons) from Singapore Management Institute. Jennifer is an avid Yoga practitioner and believes in the conscientious practice of diligence in both life and work.
Join Our Team
Lucence is a fast-growing genomic medicine company with offices in Singapore, San Francisco, Hong Kong and Suzhou.
We have assembled a dynamic team of physicians, scientists, geneticists, bioinformaticians and data analysts who are passionate about the work we do here to improve cancer care. We come from different backgrounds and nationalities but are focused on a single mission – to fight cancer and save lives.
Join our team to transform the way we fight cancer.
Click here to view our open positions.
211 Henderson Road, #04-02
Henderson Industrial Park
Tel: +65 6909 0390
Fax: +65 6725 0590
Genetics Clinic6 Napier Road, #04-03
Gleneagles Medical Centre
Tel: +65 6592 5102
Rooms 05-15, 13A/F, South Tower
World Finance Centre
Harbour City, 17 Canton Road
Tsim Sha Tsui, Kowloon
Tel: +852 5801 2340
Fax: +852 3012 9866
162 South Park Street
2F, B6 Building
218 Xinghu Street
Suzhou Industrial Park
We have received your inquiry and will get back to you soon.